Similar articles

• Defining tumor antigens: mRNA, protein or cytotoxicity?

  Lim SH, Periman P, Klug P, Weidanz J, Whitton V, Chiriva-Internati M, Wang Z, Wright S. Lim SH, et al. Trends Immunol. 2002 May;23(5):236-7; author reply 237-8. doi: 10.1016/s1471-4906(02)02196-8. Trends Immunol. 2002. PMID: 12102740 No abstract available.
• K-ras oncogene subtype mutations are associated with survival but not expression of p53, p16(INK4A), p21(WAF-1), cyclin D1, erbB-2 and erbB-3 in resected pancreatic ductal adenocarcinoma.

  Kawesha A, Ghaneh P, Andrén-Sandberg A, Ograed D, Skar R, Dawiskiba S, Evans JD, Campbell F, Lemoine N, Neoptolemos JP. Kawesha A, et al. Int J Cancer. 2000 Nov 20;89(6):469-74. doi: 10.1002/1097-0215(20001120)89:6<469::aid-ijc1>3.0.co;2-l. Int J Cancer. 2000. PMID: 11102889
• Alternative BCR/ABL splice variants in Philadelphia chromosome-positive leukemias result in novel tumor-specific fusion proteins that may represent potential targets for immunotherapy approaches.

  Volpe G, Cignetti A, Panuzzo C, Kuka M, Vitaggio K, Brancaccio M, Perrone G, Rinaldi M, Prato G, Fava M, Geuna M, Pautasso M, Casnici C, Signori E, Tonon G, Tarone G, Marelli O, Fazio VM, Saglio G. Volpe G, et al. Cancer Res. 2007 Jun 1;67(11):5300-7. doi: 10.1158/0008-5472.CAN-06-3737. Cancer Res. 2007. PMID: 17545610
• T-cell immunity to oncogenic proteins including mutated ras and chimeric bcr-abl.

  Cheever MA, Chen W, Disis ML, Takahashi M, Peace DJ. Cheever MA, et al. Ann N Y Acad Sci. 1993 Aug 12;690:101-12. doi: 10.1111/j.1749-6632.1993.tb44000.x. Ann N Y Acad Sci. 1993. PMID: 8103658 Review.
• [Progress in molecular genetics of correlating genes of breast cancer].

  Wu Y, Yang L, Wei Y. Wu Y, et al. Zhonghua Yi Xue Yi Chuan Xue Za Zhi. 2002 Apr;19(2):152-5. Zhonghua Yi Xue Yi Chuan Xue Za Zhi. 2002. PMID: 11941595 Review. Chinese.